Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation

Carcinogenesis

Volumn 28, Issue 9, 2007, Pages 1859-1866

  Sun, Daqian ^a   Ren, Hao ^a,b   Oertel, Michael ^a   Sellers, Rani S ^a   Zhu, Liang ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLIN E1; PROTEIN P27; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL REGENERATION; CONTROLLED STUDY; ENZYME ACTIVATION; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; TUMOR GROWTH;

ANIMALS; CDC2 PROTEIN KINASE; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; ENZYME ACTIVATION; GENE DELETION; HEPATITIS B SURFACE ANTIGENS; HEPATOCYTES; HUMANS; LIVER; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC;

EID: 34848868173     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm079     Document Type: Article

References (28)

1. Michalopoulos,G.K. et al. (1997) Liver regeneration. Science 276, 60-66.
2. Karnezis,A.N. et al. (2001) Loss of p27(Kip1) enhances the transplantation efficiency of hepatocytes transferred into diseased livers. J. Clin. Invest., 108, 383-390.
3. Yuan,R.H. et al. (2003) p27Kip1 inactivation provides a proliferative advantage to transplanted hepatocytes in DPPIV/Rag2 double knockout mice after repeated host liver injury. Cell Transplant., 12, 907-919.
4. Luedde,T. et al. (2003) p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver. Hepatology, 37, 833-841.
5. Fero,M.L. et al. (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature, 396, 177-180.
6. King,T.J. et al. (2005) Deficiency in the gap junction protein connexin32 alters p27Kip1 tumor suppression and MAPK activation in a tissue-specific manner. Oncogene, 24, 1718-1726.
7. Tannapfel,A. et al. (2000) Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int. J. Cancer, 89, 350-355.
8. Qin,L.F. et al. (2001) Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: Clinicopathologic correlation and survival analysis. Hum. Pathol., 32, 778-794.
9. Ito,Y. et al. (1999) Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: P27 independently predicts the recurrence. Hepatology, 30, 90-99.
10. Bruix,J. et al. (2004) Focus on hepatocellular carcinoma. Cancer Cell, 5, 215-219.
11. Chisari,F.V. et al. (1986) Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J. Virol., 60, 880-887.
12. Chisari,F.V. et al. (1989) Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59, 1145-1156.
13. Sherr,C.J. (1996) Cancer cell cycles. Science, 274, 1672-1677.
14. Hinds,P.W. (2003) Cdk2 dethroned as master of S phase entry. Cancer Cell, 3, 305-307.
15. Tetsu,O. et al. (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell, 3, 233-245.
16. Aleem,E. et al. (2005) Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat. Cell Biol., 7, 831-836.
17. Martin,A. et al. (2005) Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell, 7, 591-598.
18. Fero,M.L. et al. (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorignesis, and female sterility in p27Kip1-deficient mice. Cell, 85, 733-744.
19. Dunsford,H.A. et al. (1990) Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res. 50, 3400-3407.
20. Nakayama,K. et al. (1996) Mice lacking p27Kip1 display incresased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85, 707-720.
21. Kiyokawa,H. et al. (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell, 85 721-732.
22. Malumbres,M. et al. (2007) Cell cycle kinases in cancer. Curr. Opin. Genet. Dev., 17, 60-65.
23. Polyak,Y. et al. (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8, 9-22.
24. Toyoshima,H. et al. (1994) p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78, 67-74.
25. Chien,W.M. et al. (2006) Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1. Proc. Natl. Acad. Sci. USA, 103, 4122-4127.
26. Shaffer,D.R. et al. (2005) Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc. Natl. Acad Sci. USA, 102, 210-215.
27. Matsumoto,Y. et al. (2004) A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science, 306, 885-888.
28. Besson,A. et al. (2004) p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev., 18, 862-876.